Perioperative TTV virusload in adult lung cancer patients

Perioperative TTV virusload in adult lung cancer patients - TTV-RLK

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017352

Enrollment

Registered

2019-07-12

Start date

2019-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D38.1 C34.1 C34.2 C34.3

Interventions

Group 1: Stage I surgical resected lung cancer patients without immunesuppression

TTV (Torque-Teno-Virus) load measurement form EDTA blood preopratively, on the first and seventh postoperative days. Group 2: Stage IV lung cancer patients without immunesuppression

TTV load measurement form EDTA blood. Group 3: Non-malignant lung nodule patients with surgical resection without immunesuppression

TTV load measurement form EDTA blood preopratively, on the first postoperative and discharge days.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Stage I and IV lung cancer and non-malignant lung nodule patients

Exclusion criteria

Exclusion criteria: immunesuppression, chemotherapy, other malignant diseases

Design outcomes

Primary

Measure	Time frame
The aim of the study to determine the TTV level at diagnosis and during the early postoperitive period in lung cancer patients.	—

Countries

Germany

Contacts

Public ContactDirk Stefani

Ruhrlandklinik- Universitätsmedizin Essen

dirk.stefani@rlk.uk-essen.de+492014334878

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026